The therapeutic effect of clindamycin on Eimeria pragensis (E. pragensis) infection in C57BL/6 mice was demonstrated by suppression of oocyst production and the appearance of degenerated endogenous stages of parasite in the intestine. Short-term clindamycin treatment, from 1 to 4 days or 4 to 8 days post infection (pi) at a dose of 800 mg/kg/day was effective to reduce clinical symptoms, oocyst production and schizogonic development. Interestingly, the short-term treatment schedules allowed the development of a measurable degree of protective immunity to challenge infection in the treated mice. In contrast, clindamycin treatment for the full 12 days period, which almost completely inhibited clinical symptoms and oocyst output, prevented the full development of protective immunity in the treated mice. All these data indicate that clindamycin is efficacious as an anti-eimerian agent and that both early and late endogenous developmental stages of E. pragensis exert a deep influence on the development of effective immunity to challenge infection. KEY WORDS: clindamycin, C57BL/6 mouse, degenerate endogenous stages, E. pragensis, oocyst production.
Coccidia are a group of protozoan parasites which are very common and infect dogs, cats, rabbits, rats, mice, horses, cattle, goats, sheep, chickens and many other species of animals, as well. The coccidians that infect pets include Eimeria, Isospora, Hammondia, Toxoplasma and Neospora species. Of the infections caused by these species, two that are usually referred to as "coccidiosis" are Eimeria and Isospora infections. The clinical signs of poor weight gain, diarrhea ranging from mucoid, watery to hemorrhagic, polydipsia and sometimes acute death are seen in young animals including puppies, kittens and rabbits as well as in poultry by Eimeria infection.
Many kinds of chemotherapy are extensively used to control coccidiosis, but against a part of the currently available chemical agents the resistance by pathogens is prevalent [2, 3, 19] , and the establishment of alternative chemotherapeutic agents effective against coccidiosis is needed. On the other hand, Eimeria-mouse model has been used to investigate the immunological problem in mammalian coccidiosis. Chemical inhibition of the proliferation of parasites is a useful method to see the specific immune responses to the different developmental stages of parasite, however, it is difficult to induce the protective immunity in the Eimeriamouse model because of a lack of fully effective chemicals against the infection in mice. The lincosamide antibiotic, clindamycin, is active against apicomplexan parasites such as Plasmodium, Toxoplasma, Babesia, and the fungal pathogen Pneumocystis spp. [14] . Clindamycin is the drug of choice for prophylaxis of Toxoplasma chorioretinitis in newborn infants [20] who exhibit toxicity to standard treatment with pyrimethamine/sulphadiazine [12] and is part of the regimens recommended against both Babesia microti and B. divergens [6] . To date, the anti-eimerian effects of clindamycin have not been reported. In the present study, we determined the therapeutic effect of clindamycin to E. pragensis infection in a mouse model and assessed the interaction between treatment schedule and developing protective immunity.
MATERIALS AND METHODS
Animals: Male C57BL/6 mice, 8-9 weeks old with around 25 g body weight (BW) were purchased from Clea & Shizuoka Experimental Animal Supplier Co., Japan, housed in clean metal cages and fed with a standard diet and tap water ad libitum in an air-conditioned room (23 ± 1°C), under conventional conditions with a 12:12 hr, light: dark cycle. They were kept as outlined in the "Guide for the Care and Use of Laboratory Animals" by The Faculty of Agriculture, Miyazaki University.
Parasites: The pathogenic agent used in this study was E. pragensis [1] obtained from the Institute for Animal Health, Compton Laboratory, Compton, Newbury, Berkshire RG20 7NN, U.K., and routinely maintained in our laboratory by oral passage through C57BL/6 mice [17] .
Drug: The drug used was clindamycin phosphate "Dalacin S" (Pharmacia Co., Tokyo). Clindamycin was injected subcutaneously at doses calculated per kg BW on the basis of human therapeutic dosages.
Experimental procedures: All infective doses of E. pragensis sporulated oocysts were orally given by a gastric tube, as 100 oocysts/mouse in 0.1 ml of distilled water. Fecal pellets were collected from the infected mice between days 7 and 12 post infection (pi), and the total oocyst numbers/mouse calculated by the McMaster chamber method. Experiment 1: This experiment examined the effect of clindamycin by the total oocyst output of E. pragensis infected mice. Clindamycin-treated mice were divided into 5 groups with different doses of none, 50, 100, 400 and 800 mg/kg/day for 12 days. The mice in control groups were given distilled water only. Each group consisted of at least 4 mice. Treatment was initiated from day 1 post infection (1 dpi), and the number of oocysts was calculated as indicated above.
Experiment 2: This experiment was designed to evaluate the efficacy of different treatment schedules of clindamycin administered with a dose of 800 mg/kg/day, and the resistance of treated mice against challenge infection. Experimental mice were divided into 5 groups. Group 1 was treated with clindamycin from day 1 to day 12 pi, Group 2 from day 1 to day 4 pi, Group 3 from day 4 to day 8 pi, and Group 4 from day 8 to day 12 pi. Group 5 was injected with distilled water only as an untreated control. Each group was composed of at least 4 mice and mice were infected with 1 × 10 2 E. pragensis sporulated oocysts. To determine whether the treated mice got resistance against challenge infection, each group of mice was challenged with 1 × 10 2 E. pragensis sporulated oocysts at approximately 20 days pi. On the challenge infection, another group of mice was infected with the same dose of oocysts without clindamycin treatment as that in the control in the primary infection.
Drug efficacy was assessed by the means of total oocyst output and clinical symptoms. The results expressed by total oocyst output were statistically analyzed using student's t-test and a p value below 0.05 was considered significant. All results were presented as mean ± standard deviation (SD). Experiment 3: This experiment was carried out to evaluate the effect of clindamycin on the endogenous stages of E. pragensis using histopathological examination of tissue of the large intestine. Eight-to nine-week-old mice were divided into 3 groups: Group 1 of infected mice were injected with clindamycin from day 1 to day 4 pi, Group 2 of infected mice treated with clindamycin from day 4 to day 8 pi and Group 3 of infected mice injected with distilled water only. Each group was composed of at least 4 mice. Tissues were obtained from mice euthanised on day 3 and day 6 pi for histopathological examination. Histopathological examination was performed as follows: tissues from infectedmice were fixed in 10% neutral buffered formalin, followed by the stratified dehydration in a series of alcohol and embedment in paraffin wax. Serial sections 4 µm thick were deparaffinized, rehydrated and stained with hematoxylin and eosin [15] .
RESULTS

Dose-dependent efficacy of clindamycin:
Statistically significant reductions in oocyst output were obtained by the treatment at doses of 400 mg/kg/day and 800 mg/kg/day compared with those in unmedicated mice ( Fig. 1 ). Treatment at dose of 800 mg/kg/day completely inhibited oocyst output, whereas that at a dose of 400 mg/kg/day reduced output by approximately 75%. Mice treated either at 50 or 100 mg/kg/day produced the similar numbers of oocysts to those of unmedicated mice (Fig. 1) .
Effect of treatment schedule on oocyst output: The data obtained in Exp. 2 confirmed the almost complete and incomplete effectiveness of the treatment at a dose of 800 mg/kg/day for 12 days and from day 1 to day 4 or day 4 to day 8, respectively (Fig. 2) , that is, untreated mice produced [22.57 ± 5.12] × 10 6 oocysts, whereas those treated for 12 days [0.09 ± 0.02] × 10 6 oocysts (Group 1, p<0.001), those treated from day 1 to day 4 pi [5.62 ± 1.27] × 10 6 oocysts (Group 2, p<0.01) and those treated from day 4 to day 8 pi [1.38 ± 0.64] × 10 6 oocysts (Group 3, p<0.01). The total oocyst output obtained from the mice treated by a day 8 to 12 treatment schedule (Group 4, [13.61 ± 4.29] × 10 6 ) was not significantly different from that obtained from the unmedicated mice (Group 5).
Protection against challenge infection of mice treated with different treatment schedules in the primary infection: The primary infection of the treated or untreated mice induced protective immunity against challenge infection, so that the total oocyst outputs during challenge infection were quite lower than those during the primary infection ( Fig. 3) . Interestingly, the different schedules of treatment with clindamycin in the primary infection produced different degrees of protective immunity against the challenge infection. Specifically, the mice that treated for 12 days produced more oocysts than those in the other treated group and those in the unmedicated (DW 1-12, Group 5) during the challenge infection, although the oocyst production by this group was quite lower than that untreated in the primary infection. Mice that treated from day 1 to 4 (Group 2), day 4 to 8 (Group 3) or day 8 to 12 pi (Group 4) produced similar numbers of oocysts to those of the mice that were unmedicated during the challenge infection, that is, [2.03 ± 1.75] × 10 6 , [3.54 ± 2.59] × 10 6 and [0.08 ± 1.36] × 10 6 compared with [1.54 ± 2.67] × 10 6 . Although the group treated on day 8-12 pi showed the lower mean level of oocyst output than those treated from the day 1 to 4, day 4 to 8 pi or the untreated group, this difference in oocyst output of these latter groups was not statistically significant.
Effect of the treatment on the clinical symptoms during the primary and challenge infection of treated mice: Mice that received the 12 days treatment (Group 1) showed no clinical symptoms in such as fecal consistency, appetite and activities. Then, mice treated from days 1 to 4 (Group 2) and/or days 4 to 8 pi (Group 3) appeared healthy and active, soft feces were seen at days 8 and 9 pi. Mice treated from 8 to 12 days pi (Group 4) began to have diarrhea on day 7 pi, which progressively contained blood on days 8 and 9. These conditions appeared with depression, anorexia and dullness. Clinical conditions of the unmedicated mice (Group 5) were not significantly different from those of Group 4. When the mice treated for 12 days (Group 1) were challenged, diarrhea, anorexia and moderate weakness occurred at days 7 to 9. In contrast, after challenge infection, the mice treated for days 8 to 12 (Group 4) showed no clinical symptoms as well as the unmedicated group of mice (Group 5). Specifically, the mice that received the treatment days 1 to 4 (Group 2) or days 4 to 8 pi (Group 3) showed clear reduction in clinical symptoms as well as protection to challenge infection. Moreover, no adverse side effects were demonstrated by the treatment with clindamycin in E. pragensis infected mice. 
Morphological comparison of the endogenous stages of E. pragensis between treated and untreated infected mice:
In order to determine the effects of clindamycin treatment on the endogenous development, samples of tissues were taken from treated and untreated mice 3 days pi and at 6 days pi. The period of three days pi is the time when the second generation schizogony is in progress and most of the second trophozoites and immature schizonts were morphologically degenerated in the mice treated 1-4 days pi, whereas in the untreated group, the stages of parasite were histologically normal as well as the multinucleated immature schizonts (Figs. 4-A and B ). In the 1 to 4 day-treated mice, a few 1st-generation schizonts remained but morphologically degenerate. In contrast, numerous mature 1st-generation schizonts were observed within the epithelial cells of untreated mice (Figs. 4-C and D) . In the treated (Clm 1-4) mice, most of the degenerate immature 2nd-generation schizonts had coarse granular cytoplasm and showed poor nuclear differentiation, which made their appearance distinctly different from the normal immature schizonts seen in the untreated mice at 3 days pi (Figs. 4-E and F). Occasionally, at 6 days pi, mature 3rd -generation schizonts had merozoites with a residual body lying free within the parasitophorus vacuole. The mature schizonts in the treated (Clm 4-8) mice exhibited pycnotic degeneration, while the merozoites in a mature schizont were well developed in the untreated mice ( Fig.4-G and H) . Moreover, in the clindamycin-treated mice, the 4th-generation schizonts had a few nuclear remnants at the margin, whereas the mature 4thgeneration schizonts with a centrally located residual body surrounded by numerous small merozoites were observed in the untreated mice (Figs. 4-I and J) [16, 17] .
DISCUSSION
In the present study, clindamycin treatment was very effective at doses of 800 mg/kg/day for 1 to 12 days pi for reducing the total oocyst production and clinical symptoms in murine coccidiosis, but this treatment schedule did not induce a high degree of protective immunity in the treated mice. In contrast, clindamycin had a moderate anti-coccidial effect, when administered at a doses of 800 mg/kg/day for the shorter periods from 1 to 4 or 4 to 8 days pi of schizogony, but some parasites completed the life cycle and the level of immunity equivalent to that obtained by the late treatment schedule from day 8 to 12 and/or in the mice unmedicated in the primary infection. Therefore, the shorter period of treatment from 1 to 4 days or 4 to 8 days pi resulted in a significant reduction in the total oocyst production and an improvement in the clinical conditions.
The short-period treatment made in the early course of infection (day 1 to 4) was targeted to the early developmental stages of parasite (the 1st and 2nd -generation schizogony), whereas the intermediate (day 4 to 8) period of treatment would affect the later developmental stages of endogenous parasite. However, the late schedule of treatment (day 8 to 12) would only affect the very late stages of endogenous parasite since they would have completed the life cycle and were released into the lumen and passed out of hosts with the feces. The endogenous phase of eimerian life cycle starts when sporozoites penetrate the enterocytes and the infection can be diagnosed by the appearance and location of the developing parasites of the Eimeria spp. With E. pragensis, the 1st-generation trophozoites and immature schizonts are principally located in the cecum and colon approximately 18 hr pi and developed up to the first mature 4th-generation schizonts at 6 days pi [16] . The parasitic stages that we observed in the sections taken at days 3 and 6 pi were identical with those previously described [16] . Histological examination of the gut of infected and infected/ treated mice revealed the dramatic changes in the number and morphology of developing parasites. It is worth noting that, in vitro cultivated T. gondii, clindamycin affects the proliferation of intracellular parasites only in the 2nd parasitophorous vacuole, that is, not affecting immediately after application of the drug [5] . Surprisingly, most apicomplexan parasites including Eimeria coccidians possess a non-photosynthetic chloroplast, termed the apicoplast [4] , which might serve as the targets for the development of drug against apicomplexa [23] .
All the short-term treatment schedules were effective to generate immunity against challenge infection as well as that obtained without treatment, which resulted in the dramatic reduction in oocyst output. These data indicate that antigen load reduced by removing parasite stages in the primary infection had little effect on the degree of immunity generated in the primary infection of mice with E. pragensis. Moreover, the level of immunity generated in the primary infection was similar although the endogenous stages of parasite were reduced in number by treatment with the drug at different stages of the life cycle and this suggests that protective antigens may be encoded in multiple stages of parasite. Early studies made in the differently timed treatment schedules with sulfonamide of E. tenella infection of chickens revealed that development of the 2nd -generation schizont was necessary before protective immunity was developed [7, 13] . Thus, for E. tenella infection, at least the partial development of the 2nd-generation schizont stage, which is the large, deeply seated and pathogenic stage, is necessary to induce the protective immune response. The previous study made by the combination method of drugarrested development and transfer of infective mucosal preparations concluded that the 2nd-generation schizogenic stages were most important to stimulate protective immunity against E. maxima [18] . In contrast, studies reported that sporozoites could induce substantial protective immune responses although related with some intracellular metabolism [8] [9] [10] , and gametocyte preparations were also shown to induce immunity to challenge [21, 22] . As described above, the previously published data suggest that various developmental stages of parasite can induce substantial immunity. Interestingly, the previous study indicated that larger doses of irradiated E. maxima were required to induce immunity in chickens and suggested that dose of antigen might be important, where the important protection-inducing antigen would affect in the successive developmental stages [11] . Our data allow to put a similar interpretation on E. pragensis but also suggests that the proportions of different developmental stages of parasite may not dramatically influence the development of immunity.
In summary, we described an in vivo anti-eimerian effect of the antibiotic drug, clindamycin, at an effective dose similar to that recommended for the treatment of toxoplasmosis. The short-term treatment schedules which targeted the early and late endogenous stages of parasite are effective not only to reduce the total oocyst output and to improve the clinical symptoms but also to induce the protective immunity against the challenge infection equivalent to that induced by exposing mice to the full life cycle of parasite, that is, not intervened by drug administration. Clindamycin was thought to be useful in controlling coccidiosis in pet animals, including dogs, cats, rabbits, rats, mice, and birds.
